Striving to bring life-changing therapies to market


Verrica is advancing its lead product VP-102, a proprietary topical therapy, in many common skin indications including molluscum contagiosum (molluscum) and verruca vulgaris (common warts). Our lead product VP-102 is a topical that is applied directly to the lesions with our novel single-use applicator. Verrica is also pursuing additional common dermal indications. We recently announced the submission of a New Drug Application to the U.S. Food and Drug Administration for VP-102 for the treatment of molluscum and our positive topline results in our Phase 2 COVE-1 clinical study with VP-102 for the treatment of common warts.